Hospital
Henderson Hospital
Henderson Hospital was paid $42.37M by Medicaid between Jan 2018 and Dec 2024, across 288 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoHENDERSON HOSPITAL
HENDERSON, NV 89011
HENDERSON, NV 89011
33aNPI1003281452assigned 12/10/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.37M
24GClaims1,858,330
24DCodes billed288
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#4 of 36
Median peer was paid$7.64M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,282 | $1.70M | |
| 2019 | 311,149 | $6.37M | |
| 2020 | 259,140 | $5.33M | |
| 2021 | 282,234 | $6.47M | |
| 2022 | 308,650 | $7.50M | |
| 2023 | 323,203 | $7.94M | |
| 2024incomplete | 268,672 | $7.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 71,648 | 59,658 | $8.16M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 46,815 | 41,518 | $4.10M |
| G0378 | Hospital observation service, per hour | 8.2% | 27,843 | 19,923 | $3.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.3% | 13,703 | 11,802 | $3.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 45,965 | 38,516 | $2.41M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 8,318 | 7,253 | $1.31M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 14,510 | 12,565 | $1.27M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.7% | 4,642 | 4,023 | $1.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 57,012 | 44,905 | $1.01M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 46,932 | 34,330 | $912K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 42,394 | 31,733 | $911K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.1% | 1,955 | 1,683 | $883K |
276 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 20,597 | $510K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 12,330 | $427K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,322 | $412K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 113,528 | $371K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,443 | $368K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 10,937 | $357K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,431 | $353K |
| 80053 | Comprehensive metabolic panel | <1% | 64,141 | $312K |
| 70496 | <1% | 978 | $308K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,220 | $299K |
| 96376 | <1% | 21,044 | $293K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,116 | $286K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,562 | $281K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,483 | $275K |
| 71045 | Radiologic examination, chest; single view | <1% | 39,085 | $274K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 54,460 | $273K |
| 59025 | Fetal non-stress test | <1% | 7,303 | $261K |
| 84484 | <1% | 52,844 | $252K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,367 | $233K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,838 | $231K |
| 70498 | <1% | 858 | $231K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,270 | $230K |
| 76801 | <1% | 3,677 | $217K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 126,303 | $198K |
| 74174 | <1% | 385 | $193K | |
| 72131 | <1% | 1,522 | $192K | |
| 84702 | <1% | 29,806 | $192K | |
| 0450 | Emergency room services | <1% | 4,237 | $189K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,456 | $187K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,982 | $184K |
| 76830 | Ultrasound, transvaginal | <1% | 2,516 | $181K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 981 | $168K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 45,026 | $162K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,945 | $159K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,360 | $150K |
| 93971 | <1% | 3,054 | $145K | |
| 70486 | <1% | 1,038 | $134K | |
| 93970 | <1% | 1,726 | $132K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,627 | $128K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,418 | $124K |
| 83880 | <1% | 10,151 | $122K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,628 | $121K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,024 | $118K |
| 83690 | <1% | 32,090 | $101K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 31,070 | $88K |
| 90715 | <1% | 2,247 | $82K | |
| 83605 | <1% | 17,840 | $78K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,354 | $74K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,151 | $72K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 769 | $71K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,115 | $70K |
| 81001 | <1% | 46,108 | $67K | |
| 95819 | <1% | 339 | $65K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,875 | $64K |
| 87040 | <1% | 12,961 | $63K | |
| 73564 | <1% | 2,825 | $60K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 931 | $59K |
| 10060 | <1% | 855 | $59K | |
| 97163 | <1% | 1,963 | $54K | |
| 73630 | <1% | 3,287 | $54K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,992 | $52K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,561 | $52K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,991 | $50K |
| 83735 | <1% | 20,433 | $48K | |
| 73610 | <1% | 2,607 | $48K | |
| 85730 | <1% | 22,075 | $47K | |
| 73130 | <1% | 2,534 | $46K | |
| 85379 | <1% | 9,771 | $45K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 655 | $44K |
| 81025 | <1% | 16,763 | $44K | |
| 70491 | <1% | 269 | $43K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,420 | $42K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,423 | $41K |
| 97167 | <1% | 1,565 | $40K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 763 | $39K |
| 73110 | <1% | 1,806 | $39K | |
| 85610 | <1% | 27,148 | $37K | |
| 97162 | <1% | 1,274 | $37K | |
| 93017 | <1% | 1,929 | $34K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 585 | $34K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,012 | $34K |
| 73030 | <1% | 2,208 | $32K | |
| 12001 | <1% | 906 | $32K | |
| 80061 | Lipid panel | <1% | 5,920 | $28K |
| 97116 | <1% | 2,949 | $27K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 3,844 | $27K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,699 | $26K |
| 72100 | <1% | 1,667 | $26K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,296 | $26K |
| 87186 | <1% | 6,836 | $26K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,244 | $26K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 531 | $25K |
| 80069 | <1% | 8,682 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,480 | $23K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,371 | $22K |
| 87641 | <1% | 4,143 | $22K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 154 | $22K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,030 | $21K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 22 | $20K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,592 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 42,628 | $20K |
| 93880 | <1% | 265 | $19K | |
| 74022 | <1% | 862 | $19K | |
| 76775 | <1% | 877 | $19K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,936 | $19K |
| 82962 | <1% | 18,963 | $19K | |
| 74018 | <1% | 1,528 | $19K | |
| 96367 | <1% | 1,186 | $19K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,123 | $19K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 67 | $18K |
| 29125 | <1% | 674 | $18K | |
| 80076 | <1% | 5,239 | $18K | |
| 58661 | <1% | 20 | $18K | |
| 12011 | <1% | 400 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,110 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,264 | $17K |
| 97166 | <1% | 555 | $16K | |
| 73080 | <1% | 869 | $16K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,550 | $15K |
| 82550 | <1% | 5,846 | $15K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,949 | $15K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 257 | $14K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 137 | $13K |
| 81003 | <1% | 13,637 | $13K | |
| 85027 | <1% | 6,081 | $12K | |
| 73502 | <1% | 760 | $12K | |
| 71101 | <1% | 572 | $12K | |
| 84145 | <1% | 1,209 | $11K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 299 | $11K |
| 87077 | <1% | 2,448 | $11K | |
| 76870 | <1% | 380 | $10K | |
| 73590 | <1% | 793 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 484 | $9K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,592 | $9K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 330 | $9K |
| 84439 | <1% | 2,566 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,437 | $9K |
| 86900 | <1% | 8,048 | $8K | |
| 86901 | <1% | 8,041 | $8K | |
| 82803 | <1% | 1,419 | $8K | |
| 73090 | <1% | 484 | $7K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,330 | $7K |
| 82140 | <1% | 1,420 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,612 | $7K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 681 | $7K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $7K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,882 | $7K |
| 71250 | <1% | 49 | $7K | |
| 86140 | <1% | 3,143 | $7K | |
| 86850 | <1% | 5,462 | $6K | |
| 72128 | <1% | 68 | $6K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,843 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,375 | $6K |
| 97165 | <1% | 213 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,335 | $6K |
| Z7502 | <1% | 161 | $6K | |
| 12002 | <1% | 129 | $6K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 192 | $6K |
| 82805 | <1% | 456 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 256 | $5K |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 118 | $5K |
| 36430 | <1% | 344 | $5K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 8,957 | $5K |
| 72040 | <1% | 305 | $5K | |
| 97161 | <1% | 163 | $5K | |
| J3490 | Unclassified drugs | <1% | 403 | $5K |
| 87210 | <1% | 2,172 | $5K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 846 | $4K |
| 73140 | <1% | 260 | $4K | |
| 80074 | <1% | 315 | $4K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,746 | $4K |
| 84112 | <1% | 430 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 34 | $4K |
| 82607 | <1% | 742 | $4K | |
| 0250 | <1% | 430 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 31 | $4K |
| 84132 | <1% | 2,748 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $3K |
| 29515 | <1% | 92 | $3K | |
| 82746 | <1% | 574 | $3K | |
| 87070 | <1% | 1,230 | $3K | |
| 87205 | <1% | 2,198 | $3K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 180 | $3K |
| 87631 | <1% | 1,724 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 875 | $3K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,004 | $3K |
| 86923 | <1% | 406 | $3K | |
| 84100 | <1% | 1,795 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 354 | $3K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 457 | $3K |
| 11045 | <1% | 169 | $3K | |
| 72193 | <1% | 12 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 25 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 268 | $2K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 611 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,690 | $2K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 998 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,557 | $2K |
| 82010 | <1% | 619 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,556 | $2K |
| 58571 | <1% | 18 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 391 | $2K |
| 72072 | <1% | 99 | $2K | |
| 99201 | <1% | 104 | $2K | |
| 99070 | <1% | 264 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 216 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,269 | $2K |
| 87276 | <1% | 642 | $2K | |
| 87275 | <1% | 642 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,926 | $2K |
| 85652 | <1% | 1,544 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 669 | $2K |
| 76377 | <1% | 44 | $1K | |
| 49083 | <1% | 27 | $1K | |
| 86780 | <1% | 192 | $1K | |
| 72170 | <1% | 140 | $1K | |
| 82570 | <1% | 527 | $1K | |
| 90686 | <1% | 216 | $1K | |
| 0270 | <1% | 156 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,611 | $1K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 88 | $995.74 |
| 87081 | <1% | 594 | $991.91 | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 56 | $990.58 |
| 85018 | <1% | 1,187 | $900.84 | |
| 84550 | <1% | 383 | $877.64 | |
| 85014 | <1% | 1,160 | $875.09 | |
| 87430 | <1% | 269 | $836.55 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 517 | $830.57 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 879 | $830.39 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 248 | $773.61 |
| C1729 | Catheter, drainage | <1% | 607 | $772.06 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,225 | $647.98 |
| 87486 | <1% | 49 | $594.35 | |
| 82728 | <1% | 179 | $585.97 | |
| 83550 | <1% | 294 | $580.82 | |
| 87581 | <1% | 48 | $569.69 | |
| 87563 | <1% | 34 | $565.31 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 214 | $528.10 |
| 83540 | <1% | 290 | $500.49 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 277 | $478.73 |
| 36600 | <1% | 106 | $440.20 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 94 | $439.37 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 76 | $372.93 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 245 | $336.25 |
| 82248 | <1% | 146 | $330.10 | |
| 84156 | <1% | 212 | $329.06 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 107 | $307.28 |
| 87420 | <1% | 76 | $279.17 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 62 | $275.35 |
| 83615 | <1% | 102 | $274.33 | |
| 70360 | <1% | 13 | $270.98 | |
| 84300 | <1% | 99 | $211.25 | |
| 97597 | <1% | 43 | $193.55 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 45 | $149.35 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 205 | $134.50 |
| 73552 | <1% | 15 | $121.07 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $82.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 869 | $74.86 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 197 | $68.21 |
| 84295 | <1% | 41 | $65.87 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 63 | $65.12 |
| 85046 | <1% | 34 | $49.72 | |
| A9270 | Non-covered item or service | <1% | 24,050 | $18.35 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 27 | $12.78 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 254 | $9.90 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 187 | $1.03 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 25 | $0.06 |
| C1769 | Guide wire | 0% | 79 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 29 | $0.00 |
| 0353U | 0% | 630 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 31 | $0.00 |
| 88312 | 0% | 75 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| 87075 | 0% | 22 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.